• Login
    View Item 
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    •   Home
    • Graduate Theses, Dissertations and Projects
    • Queen's Graduate Theses and Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Secretion and Antifibrinolytic Function of TAFI from Human Platelets

    Thumbnail
    View/Open
    Schadinger_Steven_L_200909_MSc.pdf (2.515Mb)
    Date
    2009-09-26
    Author
    Schadinger, Steven Leonard
    Metadata
    Show full item record
    Abstract
    Thrombin activatable fibrinolysis inhibitor (TAFI) is a human plasma-derived zymogen that is activated through proteolytic cleavage by thrombin, thrombin in complex with thrombomodulin, or plasmin. Active TAFI attenuates fibrinolysis by removing carboxyl-terminal lysine residues from partially degraded fibrin, thereby inhibiting a potent positive feedback loop in the fibrinolytic cascade. In addition to the plasma pool of TAFI arising from expression in the liver, a distinct pool of TAFI has been reported to be present in platelets. While the antifibrinolytic effect of plasma-derived TAFI has been well-documented by in vitro and in vivo clot lysis assays, characterization of the platelet-derived form has been limited. Here, we not only confirm the presence of TAFI in the medium of washed, thrombin-stimulated platelets, but also that platelet-derived TAFI is capable of attenuating platelet-rich thrombus lysis in vitro independently of plasma TAFI using a novel thrombus lysis assay. Fluorescent thrombi were generated by suspending washed human platelets in plasma immunodepleted of TAFI containing fluorescently-labeled human fibrinogen such that the only TAFI present in the system was of platelet origin. Following platelet activation and clot retraction induced by thrombin, t-PA-dependent platelet-rich thrombus lysis was observed by removal of timed aliquots from the medium of retracted thrombi followed by measurement of fluorescence. When supplementary thrombomodulin was added to the thrombus medium, a 2.3-fold reduction in lysis rate was observed, indicating platelet-derived TAFI could attenuate the fibrinolytic cascade in vitro. Furthermore, when supplementary recombinant TAFI (rTAFI) was included in the medium, platelet-derived TAFI and rTAFI were observed to combine for greater inhibition of fibrinolysis. Taken together, these observations indicate that the secretion of platelet-derived TAFI can augment concentrations of TAFI already present in plasma to enhance attenuation of the fibrinolytic cascade. This could be significant at sites of vascular damage or regions of pathological thrombosis, where activated platelets are known to accumulate and secrete the contents of their granules. Finally, we have purified platelet-derived TAFI from platelet releasates for future characterization studies and mass spectrometry.
    URI for this record
    http://hdl.handle.net/1974/5211
    Collections
    • Queen's Graduate Theses and Dissertations
    • Biochemistry Graduate Theses (July 2007 - Sept 2016)
    Request an alternative format
    If you require this document in an alternate, accessible format, please contact the Queen's Adaptive Technology Centre

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV
     

     

    Browse

    All of QSpaceCommunities & CollectionsPublished DatesAuthorsTitlesSubjectsTypesThis CollectionPublished DatesAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    View Usage StatisticsView Google Analytics Statistics

    DSpace software copyright © 2002-2015  DuraSpace
    Contact Us
    Theme by 
    Atmire NV